Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
|Slideshows|September 17, 2018
A Rare Genetic Disorder That Causes Episodes of Flaccid Paralysis
Author(s)Veronica Hackethal, MD
About 30% of patients with periodic paralysis have unknown genetic mutation, making identification and treatment a challenge. Here: key points on genetics, testing, and subtypes of PPP.
Advertisement
Advertisement
Related to this article
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
2
Group-Based Resilience Program Improves Psychological Outcomes in Multiple Sclerosis
3
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
4
Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms
5